Made-in-Edmonton cancer drug receives Health Canada approval for Phase 1 human clinical trials
By
Hiba Kamal-Choufi
in the
Health Innovation Roundup
Edmonton-based oncology company Pacylex Pharmaceuticals has received Health Canada's approval to begin a Phase 1 clinical trial for its anti-cancer drug PCLX-001.
Pacylex CEO Michael Weickert told Taproot that the Phase 1 clinical trial is set to begin anytime between May and June at three Canadian sites: the Cross Cancer Institute in Edmonton, the British Columbia Cancer Research Center in Vancouver, and Princess Margaret Cancer Centre in Toronto.
"The approval (from Health Canada) starts the process of getting site approval. Now we need to get the clinical sites up and ready to enroll patients, get them proper training, supplies, and materials," said Weickert. "This is why it takes several months from the time you get Health Canada's approval until you can actually start giving the drug to patients."
PCLX-001 is a small molecule that is designed to kill cancer cells by targeting enzymes involved in myristoylation, a process key to the cell signaling system that is often defective in cancer cells. The molecule was originally developed by the University of Dundee as a treatment for African sleeping sickness.
"This would be a new kind of cancer medicine. We don't have anything like it already in the pharmacy," said Pacylex’s Chief Medical Officer Dr. John Mackey during a recent U of A webinar.